Chan DW - Search Results

1

SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.

McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. McLerran D, et al. Among authors: chan dw. Clin Chem. 2008 Jan;54(1):53-60. doi: 10.1373/clinchem.2007.091496. Epub 2007 Nov 16. Clin Chem. 2008. PMID: 18024530 Free PMC article.

2

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Partin AW, et al. Among authors: chan dw. J Urol. 1990 Apr;143(4):747-52. doi: 10.1016/s0022-5347(17)40079-6. J Urol. 1990. PMID: 1690309 Free article.

3

The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.

Carter HB, Partin AW, Epstein JI, Chan DW, Walsh PC. Carter HB, et al. Among authors: chan dw. J Urol. 1990 Nov;144(5):1167-70; discussion 1170-1. doi: 10.1016/s0022-5347(17)39683-0. J Urol. 1990. PMID: 1700143

4

Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.

Rock RC, Chan DW, Bruzek D, Waldron C, Oesterling J, Walsh P. Rock RC, et al. Among authors: chan dw. Clin Chem. 1987 Dec;33(12):2257-61. Clin Chem. 1987. PMID: 2446807

5

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. Partin AW, et al. Among authors: chan dw. J Urol. 1993 Jul;150(1):110-4. doi: 10.1016/s0022-5347(17)35410-1. J Urol. 1993. PMID: 7685418 Free article.

6

Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.

Pearson JD, Luderer AA, Metter EJ, Partin AW, Chan DW, Fozard JL, Carter HB. Pearson JD, et al. Among authors: chan dw. Urology. 1996 Dec;48(6A Suppl):4-9. doi: 10.1016/s0090-4295(96)00603-6. Urology. 1996. PMID: 8973693 Free article.

7

Multicenter comparison of the diagnostic performance of free prostate-specific antigen.

Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, Stamey TA, Prestigiacomo AR, Brawer MK, Petteway JC, Carlson G, Luderer AA. Thiel RP, et al. Among authors: chan dw. Urology. 1996 Dec;48(6A Suppl):45-50. doi: 10.1016/s0090-4295(96)00609-7. Urology. 1996. PMID: 8973699 Free article. Clinical Trial.

8

The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.

Pannek J, Subong EN, Jones KA, Marschke PL, Epstein JI, Chan DW, Carter HB, Luderer AA, Partin AW. Pannek J, et al. Among authors: chan dw. Urology. 1996 Dec;48(6A Suppl):51-4. doi: 10.1016/s0090-4295(96)00610-3. Urology. 1996. PMID: 8973700 Free article. Clinical Trial.

9

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.

Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Partin AW, et al. Among authors: chan dw. Urology. 1996 Dec;48(6A Suppl):55-61. doi: 10.1016/s0090-4295(96)00611-5. Urology. 1996. PMID: 8973701 Free article.

10

Prostate-specific antigen in men born with bladder exstrophy.

Silver RI, Partin AW, Epstein JI, Chan DW, Carter HB, Jeffs RD, Gearhart JP. Silver RI, et al. Among authors: chan dw. Urology. 1997 Feb;49(2):253-6. doi: 10.1016/S0090-4295(96)00438-4. Urology. 1997. PMID: 9037290 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

532 results

Search Page